MCID: CRN036
MIFTS: 68

Craniopharyngioma

Categories: Cancer diseases, Endocrine diseases, Eye diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Craniopharyngioma

MalaCards integrated aliases for Craniopharyngioma:

Name: Craniopharyngioma 12 54 60 56 6 45 15 17 74
Dysodontogenic Epithelial Tumor 54
Craniopharyngeal Duct Tumor 54
Neoplasm of Rathke's Pouch 12
Adamantinomatous Tumor 54
Rathke's Pouch Tumor 54

Characteristics:

Orphanet epidemiological data:

60
craniopharyngioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (United States),1-9/1000000 (Sweden); Age of onset: All ages;

Classifications:



Summaries for Craniopharyngioma

NIH Rare Diseases : 54 Craniopharyngioma is a slow-growing, non-cancerous brain tumor that develops near the pituitary gland (a small endocrine gland at the base of the brain which produces several important hormones) and the hypothalamus (an endocrine organ which controls the release of hormones by the pituitary gland). This tumor most commonly affects children between 5 and 10 years of age; however, adults can sometimes be affected. Although craniopharyngiomas are not cancerous, they may grow and press on nearby parts of the brain, causing symptoms including hormonal changes, vision changes, slow growth, headaches, nausea and vomiting, loss of balance, hearing loss, and changes in mood or behavior. The cause of these tumors is not well understood; however, researchers suspect that they begin to form during the early stages of embryo development in pregnancy (embryogenesis) and may result from metaplasia (abnormal transformation of cells). Treatment for craniopharyngioma varies and may involve surgery to remove the tumor, radiation therapy, chemotherapy, biologic therapy, and/or hormone therapy to replace various hormones no longer produced or secreted due to the tumor or its treatment. 

MalaCards based summary : Craniopharyngioma, also known as dysodontogenic epithelial tumor, is related to papillary craniopharyngioma and familial adenomatous polyposis 1, and has symptoms including visual disturbance An important gene associated with Craniopharyngioma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Pathways in cancer. The drugs Hydrocortisone acetate and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and hypothalamus, and related phenotypes are abnormal hypothalamus morphology and cerebral calcification

Wikipedia : 77 Craniopharyngioma is a rare type of brain tumor derived from pituitary gland embryonic tissue that... more...

Related Diseases for Craniopharyngioma

Diseases related to Craniopharyngioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
# Related Disease Score Top Affiliating Genes
1 papillary craniopharyngioma 34.2 BRAF CTNNB1 KRT7
2 familial adenomatous polyposis 1 30.4 APC CTNNB1
3 galactorrhea 30.2 IGF1 PRL
4 growth hormone deficiency 30.2 GH1 GHRL IGF1
5 ameloblastoma 30.1 KRT14 KRT8 MMP20
6 amenorrhea 29.9 GNRH1 PRL TRH
7 hypogonadotropism 29.9 GNRH1 PRL
8 adenoma 29.7 APC BRAF CTNNB1 GH1 IGF1 PRL
9 anorexia nervosa 29.5 GH1 GHRL IGF1 PRL
10 functioning pituitary adenoma 29.4 GH1 PRL TRH
11 hypothalamic disease 29.4 GH1 GNRH1 PRL
12 hyperprolactinemia 29.3 GH1 GNRH1 IGF1 PRL TRH
13 adenocarcinoma 29.3 APC BRAF CTNNB1 EPCAM VEGFA
14 prader-willi syndrome 29.2 GH1 GHRL GNRH1 IGF1 INS
15 insulin-like growth factor i 29.2 GH1 IGF1 INS PRL
16 chromophobe adenoma 29.1 GH1 GNRH1 INS PRL TRH
17 acromegaly 29.0 GH1 GHRL IGF1 INS PRL TRH
18 hyperthyroidism 28.9 GH1 GHRL INS PRL TRH
19 pituitary hormone deficiency, combined, 2 28.7 GH1 IGF1 POU1F1 PRL PROP1
20 hypopituitarism 28.6 GH1 GNRH1 IGF1 INS POU1F1 PRL
21 pituitary tumors 28.4 GH1 IGF1 POU1F1 PRL PROP1 VEGFA
22 hypothyroidism 28.2 GH1 IGF1 POU1F1 PRL PROP1 TRH
23 pituitary gland disease 27.9 GH1 GNRH1 IGF1 INS POU1F1 PRL
24 adamantinous craniopharyngioma 12.3
25 cystadenoma 11.7
26 proliferating trichilemmal cyst 10.5 KRT7 KRT8
27 endolymphatic sac tumor 10.5 KRT7 KRT8
28 benign breast adenomyoepithelioma 10.4 KRT14 KRT7
29 childhood hepatocellular carcinoma 10.4 CTNNB1 EPCAM
30 hypothalamic obesity 10.4
31 apocrine sweat gland neoplasm 10.4 KRT14 KRT7 KRT8
32 large intestine adenocarcinoma 10.4 CTNNB1 KRT7
33 brooke-spiegler syndrome 10.4 KRT14 KRT7 KRT8
34 lung acinar adenocarcinoma 10.4 CTNNB1 KRT7
35 pregnancy adenoma 10.4 KRT14 KRT7 KRT8
36 basaloid squamous cell carcinoma 10.4 KRT14 KRT7 KRT8
37 intraneural perineurioma 10.4 KRT14 KRT7 KRT8
38 primary cutaneous amyloidosis 10.4 KRT14 KRT7 KRT8
39 oncocytic breast carcinoma 10.4 KRT14 KRT7
40 secondary adrenal insufficiency 10.4 IGF1 INS
41 sweat gland cancer 10.4 KRT14 KRT7 KRT8
42 sarcoma, synovial 10.4 CTNNB1 KRT7 KRT8
43 cervical squamous cell carcinoma 10.3 CTNNB1 KRT8 MKI67
44 breast fibroadenoma 10.3 KRT14 KRT8 MKI67
45 hidrocystoma 10.3 KRT7 KRT8
46 ductal carcinoma in situ 10.3 KRT14 KRT8 MKI67
47 gastrointestinal system benign neoplasm 10.3 CTNNB1 INS KRT7
48 pituitary adenoma 10.3
49 papillary thyroid microcarcinoma 10.3 BRAF EPCAM MKI67
50 chromophobe renal cell carcinoma 10.3 EPCAM KRT7 KRT8

Graphical network of the top 20 diseases related to Craniopharyngioma:



Diseases related to Craniopharyngioma

Symptoms & Phenotypes for Craniopharyngioma

Human phenotypes related to Craniopharyngioma:

60 33 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormal hypothalamus morphology 60 33 obligate (100%) Obligate (100%) HP:0012286
2 cerebral calcification 60 33 hallmark (90%) Very frequent (99-80%) HP:0002514
3 neoplasm of the anterior pituitary 60 33 hallmark (90%) Very frequent (99-80%) HP:0011750
4 enlarged pituitary gland 60 33 hallmark (90%) Very frequent (99-80%) HP:0012505
5 intracranial cystic lesion 60 33 hallmark (90%) Very frequent (99-80%) HP:0010576
6 obesity 60 33 frequent (33%) Frequent (79-30%) HP:0001513
7 nausea and vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002017
8 papilledema 60 33 frequent (33%) Frequent (79-30%) HP:0001085
9 slow decrease in visual acuity 60 33 frequent (33%) Frequent (79-30%) HP:0007924
10 headache 60 33 frequent (33%) Frequent (79-30%) HP:0002315
11 abnormal visual field test 60 33 frequent (33%) Frequent (79-30%) HP:0030588
12 pituitary hypothyroidism 60 33 frequent (33%) Frequent (79-30%) HP:0008245
13 excessive daytime somnolence 60 33 frequent (33%) Frequent (79-30%) HP:0001262
14 bitemporal hemianopia 60 33 frequent (33%) Frequent (79-30%) HP:0030521
15 prolactin excess 60 33 frequent (33%) Frequent (79-30%) HP:0000870
16 central diabetes insipidus 60 33 frequent (33%) Frequent (79-30%) HP:0000863
17 progressive visual field defects 60 33 frequent (33%) Frequent (79-30%) HP:0007987
18 central adrenal insufficiency 60 33 frequent (33%) Frequent (79-30%) HP:0011734
19 hypogonadotrophic hypogonadism 33 frequent (33%) HP:0000044
20 hydrocephalus 60 33 occasional (7.5%) Occasional (29-5%) HP:0000238
21 sleep apnea 60 33 occasional (7.5%) Occasional (29-5%) HP:0010535
22 hearing impairment 60 33 occasional (7.5%) Occasional (29-5%) HP:0000365
23 increased intracranial pressure 60 33 occasional (7.5%) Occasional (29-5%) HP:0002516
24 type ii diabetes mellitus 60 33 occasional (7.5%) Occasional (29-5%) HP:0005978
25 optic atrophy 60 33 occasional (7.5%) Occasional (29-5%) HP:0000648
26 delayed puberty 60 33 occasional (7.5%) Occasional (29-5%) HP:0000823
27 cerebral ischemia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002637
28 polyphagia 60 33 occasional (7.5%) Occasional (29-5%) HP:0002591
29 increased susceptibility to fractures 60 33 occasional (7.5%) Occasional (29-5%) HP:0002659
30 proportionate short stature 60 33 occasional (7.5%) Occasional (29-5%) HP:0003508
31 intellectual disability 60 33 very rare (1%) Very rare (<4-1%) HP:0001249
32 seizures 60 33 very rare (1%) Very rare (<4-1%) HP:0001250
33 global developmental delay 60 33 very rare (1%) Very rare (<4-1%) HP:0001263
34 myocardial infarction 60 33 very rare (1%) Very rare (<4-1%) HP:0001658
35 postnatal growth retardation 60 33 very rare (1%) Very rare (<4-1%) HP:0008897
36 vertigo 60 33 very rare (1%) Very rare (<4-1%) HP:0002321
37 coma 60 33 very rare (1%) Very rare (<4-1%) HP:0001259
38 recurrent infections 60 33 very rare (1%) Very rare (<4-1%) HP:0002719
39 sudden loss of visual acuity 60 33 very rare (1%) Very rare (<4-1%) HP:0001117
40 abnormality of the nasal bone 60 33 very rare (1%) Very rare (<4-1%) HP:0010939
41 abnormality of the frontal bone 60 33 very rare (1%) Very rare (<4-1%) HP:0430000
42 sleep disturbance 60 Frequent (79-30%)
43 behavioral abnormality 60 Very rare (<4-1%)
44 growth delay 60 Occasional (29-5%)
45 hypogonadism 60 Frequent (79-30%)
46 low gonadotropins (secondary hypogonadism) 60 Frequent (79-30%)
47 hypopituitarism 60 Very frequent (99-80%)

UMLS symptoms related to Craniopharyngioma:


visual disturbance

GenomeRNAi Phenotypes related to Craniopharyngioma according to GeneCards Suite gene sharing:

27 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.14 GH1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.14 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.14 CTNNB1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.14 GH1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.14 POU1F1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.14 KRT8
7 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.14 GH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.14 APC
9 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.14 KRT7 KRT8 GH1 POU1F1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.14 POU1F1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.14 POU1F1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.14 GH1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.14 GH1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.14 APC CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.14 POU1F1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.14 APC KRT7 KRT8
17 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.14 CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.14 APC
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.14 GH1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.14 APC
21 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.14 POU1F1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.14 CTNNB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.14 APC CTNNB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.14 GH1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.14 KRT8
26 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.14 CTNNB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.14 CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.14 APC KRT7 KRT8 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.14 CTNNB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.14 POU1F1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.14 GH1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.14 POU1F1
33 Increased Nanog expression GR00371-A-1 9.61 MKI67 PROP1 SP7 VEGFA
34 Increased Nanog expression GR00371-A-2 9.61 VEGFA
35 Increased Nanog expression GR00371-A-3 9.61 PROP1
36 Increased Nanog expression GR00371-A-4 9.61 VEGFA
37 Increased Nanog expression GR00371-A-5 9.61 PROP1 VEGFA

MGI Mouse Phenotypes related to Craniopharyngioma:

47 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 APC BRAF CTNNB1 EPCAM GHRL GNRH1
2 endocrine/exocrine gland MP:0005379 10.41 APC BRAF CTNNB1 EPCAM GHRL GNRH1
3 growth/size/body region MP:0005378 10.4 APC BRAF CTNNB1 EPCAM GNRH1 IGF1
4 cellular MP:0005384 10.33 APC BRAF CTNNB1 EPCAM IGF1 INS
5 immune system MP:0005387 10.29 APC BRAF CTNNB1 EPCAM GNRH1 IGF1
6 hematopoietic system MP:0005397 10.28 APC BRAF CTNNB1 EPCAM GNRH1 IGF1
7 digestive/alimentary MP:0005381 10.27 APC BRAF CTNNB1 EPCAM GHRL GNRH1
8 nervous system MP:0003631 10.21 APC BRAF CTNNB1 EPCAM GNRH1 IGF1
9 integument MP:0010771 10.15 APC BRAF CTNNB1 GNRH1 IGF1 INS
10 craniofacial MP:0005382 10.13 APC BRAF CTNNB1 KRT14 MMP20 POU1F1
11 hearing/vestibular/ear MP:0005377 10.09 APC BRAF CTNNB1 IGF1 KRT14 KRT8
12 liver/biliary system MP:0005370 10.08 APC BRAF CTNNB1 GNRH1 INS KRT8
13 normal MP:0002873 10.07 APC BRAF CTNNB1 GHRL GNRH1 IGF1
14 neoplasm MP:0002006 10.06 APC BRAF CTNNB1 GNRH1 IGF1 KRT14
15 reproductive system MP:0005389 9.93 APC BRAF CTNNB1 GNRH1 IGF1 INS
16 no phenotypic analysis MP:0003012 9.88 CTNNB1 EPCAM INS MKI67 TRH VEGFA
17 renal/urinary system MP:0005367 9.86 APC BRAF CTNNB1 GNRH1 IGF1 INS
18 pigmentation MP:0001186 9.72 APC BRAF CTNNB1 KRT14 POU1F1
19 respiratory system MP:0005388 9.5 BRAF CTNNB1 IGF1 KRT14 PROP1 SP7
20 skeleton MP:0005390 9.28 APC BRAF CTNNB1 GNRH1 IGF1 INS

Drugs & Therapeutics for Craniopharyngioma

Drugs for Craniopharyngioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
5 glucocorticoids Phase 4,Phase 1
6 Hormones Phase 4,Phase 3,Phase 2,Phase 1
7 Hydrocortisone 17-butyrate 21-propionate Phase 4
8 Hydrocortisone-17-butyrate Phase 4
9 Hydrocortisone hemisuccinate Phase 4
10 Anti-Inflammatory Agents Phase 4,Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Anesthetics Phase 4,Phase 3
13 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1,Not Applicable
14
Exenatide Approved, Investigational Phase 3,Phase 2,Phase 1 141758-74-9 15991534
15
Glucagon Approved Phase 3 16941-32-5
16
Diazoxide Approved Phase 3,Phase 2 364-98-7 3019
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
19
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
21
Cisplatin Approved Phase 3 15663-27-1 441203 84093 2767
22
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
23
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
24 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
25 Incretins Phase 3,Phase 2,Phase 1
26 Glucagon-Like Peptide 1 Phase 3
27 Anti-Obesity Agents Phase 3,Phase 2,Phase 1
28 Hypoglycemic Agents Phase 3,Phase 2,Phase 1
29 Antihypertensive Agents Phase 3,Phase 2
30 Vasodilator Agents Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 3,Phase 1
32 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Emetics Phase 3
34 BB 1101 Phase 3,Phase 1
35 Autonomic Agents Phase 3,Phase 1
36 Antiemetics Phase 3,Phase 1
37 Liver Extracts Phase 3,Phase 1,Phase 2
38 Anesthetics, Intravenous Phase 3
39 Cola Phase 3,Phase 1
40 Central Nervous System Depressants Phase 3,Phase 1
41 Narcotics Phase 3
42 Anesthetics, General Phase 3
43 Adjuvants, Anesthesia Phase 3
44 Analgesics, Opioid Phase 3
45 Analgesics Phase 3
46 Cholinesterase Inhibitors Phase 3,Phase 2,Early Phase 1
47 Nootropic Agents Phase 3,Phase 2,Early Phase 1
48 Cholinergic Agents Phase 3,Phase 2,Early Phase 1
49 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Early Phase 1
50
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
3 Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Completed NCT02860923 Phase 3 Exenatide;Placebo
4 Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
5 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
8 Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Recruiting NCT02664441 Phase 3 Exenatide;placebo
9 90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors Recruiting NCT02081768 Phase 3
10 Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery Completed NCT01964300 Phase 2
11 Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy Completed NCT00892073 Phase 2 Diazoxide;Metformin
12 Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor Completed NCT01484873 Phase 2 Exenatide
13 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
14 An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury Completed NCT02063295 Phase 2 ZGN-440 sterile diluent;ZGN-440 for injectable suspension
15 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
16 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
17 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
18 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors Completed NCT00003461 Phase 1, Phase 2
19 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
20 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
21 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
22 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
23 A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection Recruiting NCT02792582 Phase 2
24 Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma Recruiting NCT03224767 Phase 2 Vemurafenib;Cobimetinib
25 Intranasal Oxytocin in Hypothalamic Obesity Recruiting NCT02849743 Phase 2 Syntocinon;Placebo (for Syntocinon)
26 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Recruiting NCT03194906 Phase 2 Memantine
27 Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Recruiting NCT02367859 Phase 2 Dabrafenib;Trametinib
28 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2 Methionine
29 A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection Active, not recruiting NCT01419067 Phase 2 ^1^8F-fluorodeoxyglucose;^1^1C-methionine
30 Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma) Active, not recruiting NCT02842723 Phase 2
31 Effects of Exenatide on Hypothalamic Obesity Active, not recruiting NCT01061775 Phase 1, Phase 2 Exenatide
32 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Active, not recruiting NCT01966809 Phase 2 Photofrin photodynamic therapy.
33 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
34 Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy Terminated NCT01348607 Phase 2 methylphenidate hydrochloride;modafinil;placebo
35 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
36 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
37 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
38 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
39 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
40 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
41 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
42 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
43 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
44 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
45 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
46 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
47 Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors Completed NCT01682746 Phase 1 Photofrin (porfimer sodium) & photodynamic therapy.
48 O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors Completed NCT00003765 Phase 1 O6-benzylguanine;carmustine
49 SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
50 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus

Search NIH Clinical Center for Craniopharyngioma

Cochrane evidence based reviews: craniopharyngioma

Genetic Tests for Craniopharyngioma

Anatomical Context for Craniopharyngioma

MalaCards organs/tissues related to Craniopharyngioma:

42
Brain, Pituitary, Hypothalamus, Bone, Testes, Liver, Spinal Cord

Publications for Craniopharyngioma

Articles related to Craniopharyngioma:

(show top 50) (show all 1460)
# Title Authors Year
1
Pituitary Adenoma and Craniopharyngioma Collision Tumor: Diagnostic, Treatment Considerations, and Review of the Literature. ( 30326307 )
2019
2
Trans-eyebrow supraorbital keyhole approach in suprasellar and third ventricular craniopharyngioma surgery: the experience of 27 cases and a literature review. ( 30392089 )
2019
3
Management of hypothalamic disease in patients with craniopharyngioma. ( 30614015 )
2019
4
Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach. ( 30616515 )
2019
5
Management of Craniopharyngioma. ( 30640850 )
2019
6
SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. ( 30645190 )
2019
7
Growth hormone replacement therapy improves hypopituitarism-associated hypoxemia in a patient after craniopharyngioma surgery: A case report. ( 30653131 )
2019
8
Adipsic diabetes insipidus secondary to craniopharyngioma resection. ( 30709829 )
2019
9
Patterns of Care in Pediatric Craniopharyngioma: Outcomes Following Definitive Radiotherapy. ( 30711960 )
2019
10
Craniopharyngioma: 10 Selected Works That Provide Comprehensive and Valuable Insight into These Complex Tumors. ( 30716873 )
2019
11
In Reply to the Letter to the Editor "Craniopharyngioma: 10 Selected Works Which Provide Comprehensive and Valuable Insight into These Complex Tumors". ( 30716874 )
2019
12
Subfrontal Infrachiasmatic Approach to a Craniopharyngioma Resection: 2-Dimensional Operative Video. ( 30726971 )
2019
13
Efficacy of Direct Revascularization Surgery for Hemorrhagic Moyamoya Syndrome As a Late Complication of Cranial Irradiation for Childhood Craniopharyngioma. ( 30772161 )
2019
14
Intrachiasmatic craniopharyngioma: Assessment of visual outcome with optical coherence tomography after complete surgical removal. ( 30775061 )
2019
15
MANAGEMENT OF ENDOCRINE DISEASE: Childhood-onset Craniopharyngioma: state of the art of care in 2018. ( 30817319 )
2019
16
Anterior cerebral artery rupture during extended endoscopic endonasal transsphenoidal approach for severely calcified craniopharyngioma. ( 30844531 )
2019
17
An ectopic recurrent craniopharyngioma of the temporal lobe: Case report and review of the literature. ( 30877004 )
2019
18
Endoscopic Transsphenoidal Resection of Craniopharyngioma. ( 29404252 )
2018
19
Rare case of malignant craniopharyngioma reactive to adjunctive stereotactic radiotherapy and chemotherapy; Case report and review. ( 29933092 )
2018
20
Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma. ( 29681617 )
2018
21
The diagnostic value of preoperative inflammatory markers in craniopharyngioma: a multicenter cohort study. ( 29388032 )
2018
22
Expanded Endoscopic Endonasal Resection of Retrochiasmatic Craniopharyngioma. ( 29404248 )
2018
23
Childhood Craniopharyngioma: A 22-Year Challenging Follow-Up in a Single Center. ( 29959763 )
2018
24
Micturition Disorders as the First Symptom of Multiple Pituitary Hormone Deficiency Caused by Craniopharyngioma. ( 29314378 )
2018
25
Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma. ( 29971569 )
2018
26
A Craniopharyngioma Associated With Elevated Cerebrospinal Fluid HCG Concentrations Misdiagnosed as a Germinoma. ( 29963005 )
2018
27
Extended Endoscopic Endonasal Approach for Suprasellar Craniopharyngioma. ( 29404249 )
2018
28
Predicting parental distress among children newly diagnosed with craniopharyngioma. ( 29932288 )
2018
29
Letter to the Editor Regarding &amp;quot;Anatomic Dissection of Arachnoid Membranes Encircling the Pituitary Stalk on Fresh Non-Formalin-Fixed Specimens: Anatomoradiologic Correlations and Clinical Applications in Craniopharyngioma Surgery&amp;quot;. ( 29232813 )
2018
30
Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma. ( 29520296 )
2018
31
A novel endoscopic classification for craniopharyngioma based on its origin. ( 29977006 )
2018
32
A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )
2018
33
Characterization of the murine orthotopic adamantinomatous craniopharyngioma PDX model by MRI in correlation with histology. ( 29795641 )
2018
34
Radiation therapy rather than prior surgery reduces extent of resection during endonasal endoscopic reoperation for craniopharyngioma. ( 29802559 )
2018
35
Chemical meningitis from a leaking craniopharyngioma: a case report. ( 29663082 )
2018
36
The development of hypothalamic obesity in craniopharyngioma patients: A risk factor analysis in a well-defined cohort. ( 29314661 )
2018
37
Fusiform dilatation of the internal carotid artery following childhood craniopharyngioma resection treated by endovascular flow diversion-A case report and literature review. ( 29805079 )
2018
38
Clinical outcomes of childhood craniopharyngioma: can we do better? ( 29934877 )
2018
39
Combined endoscopic approach in the management of suprasellar craniopharyngioma. ( 29435609 )
2018
40
Interventions for the treatment of craniopharyngioma-related hypothalamic obesity: a systematic review. ( 29945001 )
2018
41
Endoscopic Endonasal Resection of Retrochiasmatic Craniopharyngioma with Fascia Lata Button and Nasoseptal Flap Reconstruction. ( 29404247 )
2018
42
Abscess inside craniopharyngioma: diagnostic and management implications. ( 29431099 )
2018
43
Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review. ( 29901583 )
2018
44
Letter to the Editor. The role of preoperative MRI in predicting craniopharyngioma behavior. ( 29726783 )
2018
45
Craniopharyngioma - a chronic disease. ( 29442345 )
2018
46
Intraventricular recurrence of a craniopharyngioma: case report. ( 29957141 )
2018
47
Extended Endoscopic Endonasal Approach for Craniopharyngioma Removal. ( 29404250 )
2018
48
Phosphorus-32 interstitial radiotherapy for recurrent craniopharyngioma: Expressions of vascular endothelial growth factor and its receptor-2 and imaging features of tumors are associated with tumor radiosensitivity. ( 29952957 )
2018
49
Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. ( 29701552 )
2018
50
Limits of endoscopic endonasal surgery for craniopharyngioma. ( 29378389 )
2018

Variations for Craniopharyngioma

ClinVar genetic disease variations for Craniopharyngioma:

6 (show all 45)
# Gene Variation Type Significance SNP ID Assembly Location
1 BMPR1A NM_004329.2(BMPR1A): c.499A> T (p.Met167Leu) single nucleotide variant Uncertain significance rs200951235 GRCh37 Chromosome 10, 88659852: 88659852
2 BMPR1A NM_004329.2(BMPR1A): c.499A> T (p.Met167Leu) single nucleotide variant Uncertain significance rs200951235 GRCh38 Chromosome 10, 86900095: 86900095
3 PTCH1 NM_000264.4(PTCH1): c.113G> A (p.Gly38Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs143494325 GRCh37 Chromosome 9, 98270531: 98270531
4 PTCH1 NM_000264.4(PTCH1): c.113G> A (p.Gly38Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs143494325 GRCh38 Chromosome 9, 95508249: 95508249
5 SMARCA4 NM_001128849.1(SMARCA4): c.442G> A (p.Gly148Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs138689221 GRCh38 Chromosome 19, 10986275: 10986275
6 SMARCA4 NM_001128849.1(SMARCA4): c.442G> A (p.Gly148Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs138689221 GRCh37 Chromosome 19, 11096951: 11096951
7 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
8 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh38 Chromosome 3, 41224606: 41224606
9 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
10 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh38 Chromosome 3, 41224613: 41224613
11 BRCA1 NM_007294.3(BRCA1): c.5123C> T (p.Ala1708Val) single nucleotide variant Uncertain significance rs28897696 GRCh37 Chromosome 17, 41215920: 41215920
12 BRCA1 NM_007294.3(BRCA1): c.5123C> T (p.Ala1708Val) single nucleotide variant Uncertain significance rs28897696 GRCh38 Chromosome 17, 43063903: 43063903
13 PTPN11 NM_002834.4(PTPN11): c.925A> G (p.Ile309Val) single nucleotide variant Benign rs201787206 GRCh37 Chromosome 12, 112915526: 112915526
14 PTPN11 NM_002834.4(PTPN11): c.925A> G (p.Ile309Val) single nucleotide variant Benign rs201787206 GRCh38 Chromosome 12, 112477722: 112477722
15 TSC1 NM_000368.4(TSC1): c.1231C> A (p.Leu411Ile) single nucleotide variant Uncertain significance rs397514840 GRCh37 Chromosome 9, 135785990: 135785990
16 TSC1 NM_000368.4(TSC1): c.1231C> A (p.Leu411Ile) single nucleotide variant Uncertain significance rs397514840 GRCh38 Chromosome 9, 132910603: 132910603
17 TSC2 NM_000548.3(TSC2): c.3803G> A (p.Arg1268His) single nucleotide variant Conflicting interpretations of pathogenicity rs200577441 GRCh37 Chromosome 16, 2131788: 2131788
18 TSC2 NM_000548.3(TSC2): c.3803G> A (p.Arg1268His) single nucleotide variant Conflicting interpretations of pathogenicity rs200577441 GRCh38 Chromosome 16, 2081787: 2081787
19 APC NM_000038.5(APC): c.3183_3187delACAAA (p.Gln1062Terfs) deletion Pathogenic rs587779352 GRCh37 Chromosome 5, 112174474: 112174478
20 APC NM_000038.5(APC): c.3183_3187delACAAA (p.Gln1062Terfs) deletion Pathogenic rs587779352 GRCh38 Chromosome 5, 112838777: 112838781
21 CDH1 NM_004360.5(CDH1): c.1225T> C (p.Trp409Arg) single nucleotide variant Uncertain significance rs587778176 GRCh37 Chromosome 16, 68847303: 68847303
22 CDH1 NM_004360.5(CDH1): c.1225T> C (p.Trp409Arg) single nucleotide variant Uncertain significance rs587778176 GRCh38 Chromosome 16, 68813400: 68813400
23 TSC2 NM_000548.3(TSC2): c.3846_3855delCTGCCAAGGAinsG (p.Ser1282_Gly1285delinsArg) indel Conflicting interpretations of pathogenicity rs587778732 GRCh38 Chromosome 16, 2082467: 2082476
24 TSC2 NM_000548.3(TSC2): c.3846_3855delCTGCCAAGGAinsG (p.Ser1282_Gly1285delinsArg) indel Conflicting interpretations of pathogenicity rs587778732 GRCh37 Chromosome 16, 2132468: 2132477
25 SUFU NM_016169.3(SUFU): c.839G> A (p.Arg280Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs145704867 GRCh37 Chromosome 10, 104356979: 104356979
26 SUFU NM_016169.3(SUFU): c.839G> A (p.Arg280Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs145704867 GRCh38 Chromosome 10, 102597222: 102597222
27 CTNNB1 NM_001904.3(CTNNB1): c.100G> A (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh37 Chromosome 3, 41266103: 41266103
28 CTNNB1 NM_001904.3(CTNNB1): c.100G> A (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh38 Chromosome 3, 41224612: 41224612
29 CTNNB1 NM_001904.3(CTNNB1): c.100G> C (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh37 Chromosome 3, 41266103: 41266103
30 CTNNB1 NM_001904.3(CTNNB1): c.100G> C (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh38 Chromosome 3, 41224612: 41224612
31 TSC1 NM_000368.4(TSC1): c.1355G> C (p.Gly452Ala) single nucleotide variant Uncertain significance rs371093730 GRCh37 Chromosome 9, 135782201: 135782201
32 TSC1 NM_000368.4(TSC1): c.1355G> C (p.Gly452Ala) single nucleotide variant Uncertain significance rs371093730 GRCh38 Chromosome 9, 132906814: 132906814
33 TSC2 NM_000548.3(TSC2): c.3038A> G (p.Asp1013Gly) single nucleotide variant Uncertain significance rs1060500961 GRCh37 Chromosome 16, 2129104: 2129104
34 TSC2 NM_000548.3(TSC2): c.3038A> G (p.Asp1013Gly) single nucleotide variant Uncertain significance rs1060500961 GRCh38 Chromosome 16, 2079103: 2079103
35 NF1 NM_000267.3(NF1): c.4773G> A (p.Arg1591=) single nucleotide variant Conflicting interpretations of pathogenicity rs1555533268 GRCh37 Chromosome 17, 29652838: 29652838
36 NF1 NM_000267.3(NF1): c.4773G> A (p.Arg1591=) single nucleotide variant Conflicting interpretations of pathogenicity rs1555533268 GRCh38 Chromosome 17, 31325820: 31325820
37 MSH6 NM_000179.2(MSH6): c.1657A> C (p.Thr553Pro) single nucleotide variant Uncertain significance GRCh37 Chromosome 2, 48026779: 48026779
38 MSH6 NM_000179.2(MSH6): c.1657A> C (p.Thr553Pro) single nucleotide variant Uncertain significance GRCh38 Chromosome 2, 47799640: 47799640
39 PHOX2B NM_003924.3(PHOX2B): c.556G> A (p.Glu186Lys) single nucleotide variant Uncertain significance GRCh38 Chromosome 4, 41746196: 41746196
40 PHOX2B NM_003924.3(PHOX2B): c.556G> A (p.Glu186Lys) single nucleotide variant Uncertain significance GRCh37 Chromosome 4, 41748213: 41748213
41 PTCH1 NM_000264.4(PTCH1): c.203G> A (p.Gly68Glu) single nucleotide variant Uncertain significance GRCh38 Chromosome 9, 95506598: 95506598
42 PTCH1 NM_000264.4(PTCH1): c.203G> A (p.Gly68Glu) single nucleotide variant Uncertain significance GRCh37 Chromosome 9, 98268880: 98268880
43 KRAS NM_004985.4: c.547_552delACAAAG deletion Uncertain significance GRCh38 Chromosome 12, 25209815: 25209820
44 KRAS NM_004985.4: c.547_552delACAAAG deletion Uncertain significance GRCh37 Chromosome 12, 25362744: 25362749
45 ERCC2 NM_000400.3: c.1367_1369delTCA undetermined variant Likely pathogenic GRCh38 Chromosome 19, 45357482: 45357484

Cosmic variations for Craniopharyngioma:

9 (show all 22)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5672 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>A p.D32N 3:41224606-41224606 0
2 COSM5679 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.110C>G p.S37C 3:41224622-41224622 0
3 COSM5669 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>T p.S33F 3:41224610-41224610 0
4 COSM5668 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>C p.D32H 3:41224606-41224606 0
5 COSM5684 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.100G>C p.G34R 3:41224612-41224612 0
6 COSM5662 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.110C>T p.S37F 3:41224622-41224622 0
7 COSM5674 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.104T>G p.I35S 3:41224616-41224616 0
8 COSM5676 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.122C>T p.T41I 3:41224634-41224634 0
9 COSM5683 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.97T>G p.S33A 3:41224609-41224609 0
10 COSM5682 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.97T>C p.S33P 3:41224609-41224609 0
11 COSM5677 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>G p.S33C 3:41224610-41224610 0
12 COSM5691 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.95A>T p.D32V 3:41224607-41224607 0
13 COSM5681 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.95A>G p.D32G 3:41224607-41224607 0
14 COSM5663 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.133T>C p.S45P 3:41224645-41224645 0
15 COSM5664 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.121A>G p.T41A 3:41224633-41224633 0
16 COSM5661 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.94G>T p.D32Y 3:41224606-41224606 0
17 COSM5673 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.98C>A p.S33Y 3:41224610-41224610 0
18 COSM5701 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.122C>G p.T41S 3:41224634-41224634 0
19 COSM5758 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.127G>A p.A43T 3:41224639-41224639 0
20 COSM5687 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.109T>C p.S37P 3:41224621-41224621 0
21 COSM5686 CTNNB1 pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.100G>A p.G34R 3:41224612-41224612 0
22 COSM476 BRAF pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous c.1799T>A p.V600E 7:140753336-140753336 0

Expression for Craniopharyngioma

Search GEO for disease gene expression data for Craniopharyngioma.

Pathways for Craniopharyngioma

Pathways related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.07 APC BRAF CTNNB1 GH1 GNRH1 IGF1
2 12.68 APC BRAF CTNNB1 IGF1 VEGFA
3
Show member pathways
12.55 BRAF CTNNB1 IGF1 INS VEGFA
4
Show member pathways
12.54 APC BRAF CTNNB1 IGF1 INS VEGFA
5
Show member pathways
12.35 APC BRAF IGF1 INS
6
Show member pathways
12.33 APC CTNNB1 GH1 IGF1 INS PRL
7 12.1 BRAF CTNNB1 IGF1 VEGFA
8 11.98 APC BRAF CTNNB1 VEGFA
9
Show member pathways
11.93 APC BRAF CTNNB1 GH1 GNRH1 IGF1
10 11.83 EPCAM IGF1 INS VEGFA
11 11.79 CTNNB1 GH1 IGF1 INS
12 11.75 IGF1 INS VEGFA
13 11.71 BRAF CTNNB1 KRT14
14 11.64 KRT14 POU1F1 PRL
15 11.6 APC BRAF CTNNB1 IGF1
16 11.58 CTNNB1 KRT8 MKI67
17 11.51 GH1 IGF1 VEGFA
18 11.29 IGF1 INS VEGFA
19
Show member pathways
11.28 CTNNB1 GH1 GHRL IGF1 INS

GO Terms for Craniopharyngioma

Cellular components related to Craniopharyngioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 GH1 GHRL GNRH1 IGF1 INS MMP20
2 extracellular region GO:0005576 9.97 GH1 GHRL GNRH1 IGF1 INS MMP20
3 keratin filament GO:0045095 9.61 KRT14 KRT7 KRT8
4 secretory granule GO:0030141 9.46 TRH VEGFA
5 beta-catenin destruction complex GO:0030877 9.4 APC CTNNB1
6 cell periphery GO:0071944 9.33 CTNNB1 KRT14 KRT8
7 Wnt signalosome GO:1990909 9.26 APC CTNNB1
8 lateral plasma membrane GO:0016328 9.13 APC CTNNB1 EPCAM
9 endosome lumen GO:0031904 8.8 GH1 INS PRL

Biological processes related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 BRAF CTNNB1 IGF1 INS VEGFA
2 positive regulation of cell migration GO:0030335 9.87 APC IGF1 INS VEGFA
3 positive regulation of cold-induced thermogenesis GO:0120162 9.78 APC GHRL VEGFA
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 GH1 IGF1 VEGFA
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 GH1 IGF1 INS
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 GH1 IGF1 VEGFA
7 negative regulation of apoptotic process GO:0043066 9.7 BRAF CTNNB1 GHRL GNRH1 IGF1 PROP1
8 response to nutrient levels GO:0031667 9.63 GH1 GHRL PRL
9 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.6 GH1 PRL
10 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.59 GH1 IGF1
11 positive regulation of growth GO:0045927 9.58 GH1 GHRL
12 adenohypophysis development GO:0021984 9.54 POU1F1 PROP1
13 positive regulation of multicellular organism growth GO:0040018 9.5 GH1 GHRL POU1F1
14 positive regulation of cell proliferation GO:0008284 9.5 CTNNB1 EPCAM IGF1 INS POU1F1 PRL
15 positive regulation of epithelial cell proliferation GO:0050679 9.49 IGF1 VEGFA
16 negative regulation of feeding behavior GO:2000252 9.43 INS TRH
17 cell fate specification GO:0001708 9.43 APC CTNNB1 POU1F1
18 positive regulation of glucose transmembrane transport GO:0010828 9.4 BRAF GH1
19 somatotropin secreting cell differentiation GO:0060126 9.37 POU1F1 PROP1
20 ovulation cycle GO:0042698 9.26 GNRH1
21 regulation of signaling receptor activity GO:0010469 9.23 GH1 GHRL GNRH1 IGF1 INS PRL
22 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 CTNNB1 EPCAM IGF1 POU1F1 PROP1 SP7

Molecular functions related to Craniopharyngioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 GH1 GHRL GNRH1 IGF1 INS PRL
2 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Craniopharyngioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....